A Multicenter, Randomized, Dose-Ranging, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines
Latest Information Update: 11 May 2023
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Glabellar lines
- Focus Therapeutic Use
- Sponsors Galderma; Q-Med
- 21 Mar 2023 Results (from 3 studies NCT03736928,NCT03960957and An open-label extension study) assessing the effect of ABO on glabellar lines at rest presented at the American Academy of Dermatology annual Meeting 2023.
- 31 May 2022 According to a Galderma media release, Pooled data from NCT03736928, Phase 2; NCT03960957, Phase 3; NCT03687736, Phase 4 will be presented at the upcoming International Master Course on Aging Science (IMCAS) World Congress 2022 in Paris from June 3-5, 2022
- 25 Apr 2021 Results assessing efficacy and safety of AbobotulinumtoxinA for the treatment of Moderate-to-Severe Glabellar Lines presented at the American Academy of Dermatology Virtual Meeting Experience 2021